Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Sig... Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells. Mehr anzeigen
Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm PR Newswire NEW YORK, Dec. 19, 2024 NEW YORK, Dec. 19, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.1697 | 17.6715609705 | 0.9603 | 1.14 | 0.8099 | 1264743 | 0.90716796 | CS |
| 4 | -0.145 | -11.3725490196 | 1.275 | 1.38 | 0.8099 | 693357 | 1.02432661 | CS |
| 12 | -0.02 | -1.73913043478 | 1.15 | 1.555 | 0.7962 | 573942 | 1.12590306 | CS |
| 26 | 0.27035 | 31.4488454604 | 0.85965 | 1.555 | 0.535 | 551919 | 1.00797767 | CS |
| 52 | 0.045 | 4.14746543779 | 1.085 | 1.69 | 0.535 | 671011 | 1.12185915 | CS |
| 156 | -6.37 | -84.9333333333 | 7.5 | 8.73 | 0.535 | 1079351 | 3.94849141 | CS |
| 260 | -83.72 | -98.6682380672 | 84.85 | 157.98 | 0.535 | 941247 | 14.97898128 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
